Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

Q2 2026 13F · SEC CIK 1615982

Venrock Adviser, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value
$3.3B
Reported positions
33
Top holdings a year, 3 yrs
+67.8%
Assets under management
$4.5B

Venrock Adviser, LLC is a hedge fund that reported 33 positions worth $3.3B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Apogee Therapeutics Inc (APGE, 34.2%), Oruka Therapeutics Inc (ORKA, 12.0%), Erasca, Inc. (ERAS, 9.9%). A portfolio copying its top holdings returned 67.8% a year over the last 3 years, against 22.3% for the S&P 500.

Venrock Adviser, LLC holdings all 33 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Venrock Adviser, LLC 13F holdings
Stock% of 13F valueShare changeReported value
APGEApogee Therapeutics Inc34.2%+0.0%$1.1B
ORKAOruka Therapeutics Inc12.0%+0.0%$394.8M
ERASErasca, Inc.9.9%+9.2%$327.8M
SYRESpyre Therapeutics8.0%-19.0%$265.0M
DNTHDianthus Therapeutics Inc3.5%+0.0%$115.0M
OCULOcular Therapeutix Inc3.1%+0.0%$101.6M
GLTODamora Therapeutics Inc2.8%+0.0%$93.7M
SVRASavara Inc2.8%+7.3%$90.8M
008064206Jade Biosciences Inc2.2%+0.0%$71.6M
COGTCogent Biosciences Inc1.9%-17.9%$63.6M
VRDNViridian Therapeutics Inc1.8%-16.1%$59.8M
VORVor Biopharma Inc1.7%+0.0%$56.0M
DYNDyne Therapeutics Inc1.5%+0.0%$48.3M
MAZEMaze Therapeutics Inc1.4%+0.0%$47.8M
RLMDRelmada Therapeutics Inc1.4%+41.3%$47.4M
ORICOric Pharmaceuticals Inc1.4%+0.0%$46.8M
CBIOCrescent Biopharma Inc1.2%+0.0%$38.4M
ZURAZura Bio Ltd1.2%+0.0%$38.0M
ANLAdlai Nortye Ltd1.1%+0.0%$36.9M
ELVNEnliven Therapeutics Inc0.8%-69.5%$26.7M
23256X407Cybin Inc0.8%+0.0%$25.5M
CGEMCullinan Therapeutics Inc0.8%+0.0%$25.1M
IPSCCentury Therapeutics Inc0.6%+0.0%$21.3M
ARTVArtiva Biotherapeutics Inc0.6%+27.0%$19.8M
CTMXCytomx Therapeutics Inc.0.6%-50.1%$18.7M
ACHVAchieve Life Science Inc0.5%—$18.0M
PBLSParabilis Medicines, Inc.0.5%—$17.1M
SRZNSurrozen Inc0.5%+0.0%$16.4M
KRROKorro Bio Inc0.4%+0.0%$13.3M
ANROAlto Neuroscience Inc0.4%+0.0%$13.2M
XFORX4 Pharmaceuticals Inc0.3%+485.2%$9.0M
RACCResearch Alliance Corp III0.1%—$3.2M
INMInMed Pharmaceuticals Inc0.0%—$51K

What Venrock Adviser, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Added to

Reduced

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year
+104.9% /yr
S&P 500 +11.7%
3 years
+67.8% /yr
S&P 500 +22.3%
5 years
+9.1% /yr
S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter13F valuePositions
Q2 2026$3.3B33
Q1 2026$2.7B33
Q4 2025$2.0B27
Q3 2025$1.8B33
Q2 2025$1.3B31
Q1 2025$1.2B37
Q4 2024$1.5B37
Q3 2024$1.9B38
Q2 2024$1.6B35
Q1 2024$2.1B38
Q4 2023$1.5B36
Q3 2023$949.9M37

Questions about Venrock Adviser, LLC's portfolio

What stocks does Venrock Adviser, LLC own?

Venrock Adviser, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 33 positions worth $3.3B. The largest are Apogee Therapeutics Inc (APGE) at 34.2%, Oruka Therapeutics Inc (ORKA) at 12.0%, Erasca, Inc. (ERAS) at 9.9%, Spyre Therapeutics (SYRE) at 8.0% and Dianthus Therapeutics Inc (DNTH) at 3.5%.

What did Venrock Adviser, LLC buy last quarter?

In Q2 2026, Venrock Adviser, LLC added a new position in Achieve Life Science Inc (ACHV), a new position in Parabilis Medicines, Inc. (PBLS), a new position in Research Alliance Corp III (RACC), a new position in InMed Pharmaceuticals Inc (INM), X4 Pharmaceuticals Inc (XFOR) (+485.2% shares), Relmada Therapeutics Inc (RLMD) (+41.3% shares) and Artiva Biotherapeutics Inc (ARTV) (+27.0% shares), compared with its Q1 2026 filing.

What did Venrock Adviser, LLC sell last quarter?

In Q2 2026, Venrock Adviser, LLC sold all of Kalvista Pharmaceuticals Inc (KALV), sold all of enGene Holdings Inc. (ENGN), sold all of Tenax Therapeutics Inc (TENX), sold all of Septerna Inc (SEPN), Enliven Therapeutics Inc (ELVN) (-69.5% shares), Cytomx Therapeutics Inc. (CTMX) (-50.1% shares) and Spyre Therapeutics (SYRE) (-19.0% shares), compared with its Q1 2026 filing.

How has Venrock Adviser, LLC's portfolio performed?

A portfolio copying Venrock Adviser, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +67.8% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +104.9% against +11.7%. Over 5 years: +9.1% a year against +10.6%.

When is Venrock Adviser, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Venrock Adviser, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Venrock Adviser, LLC manage?

Venrock Adviser, LLC reported $4.5B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $3.3B.